PMID- 18940574
OWN - NLM
STAT- MEDLINE
DCOM- 20090206
LR  - 20081022
IS  - 0889-8561 (Print)
IS  - 0889-8561 (Linking)
VI  - 28
IP  - 4
DP  - 2008 Nov
TI  - Subcutaneous administration of IgG.
PG  - 779-802, viii
LID - 10.1016/j.iac.2008.07.002 [doi]
AB  - The availability of IgG preparations that could be administered safely by the 
      intravenous route was finally achieved in the early to mid-1980s. Intravenous 
      immunoglobulin (IVIG) revolutionized the treatment of primary immune deficiency 
      diseases (PIDD) and led to the discovery of the therapeutic value of high-dose 
      IgG in autoimmune and inflammatory diseases not associated with PIDD. Improved 
      therapy has improved outcomes and expectations, and most PIDD patients can lead 
      fully active and productive lives. Administration of IgG by the subcutaneous 
      route is effective and safe and overcomes obstacles to the use of IVIG in some 
      patients. Many patients find administration of subcutaneous IgG at home more 
      convenient than receiving IVIG at the Doctor's office or hospital. The coming 
      years will see increased use of subcutaneous immunoglobulin in PIDD, which will 
      be facilitated by advances leading to higher-concentration IgG products and 
      easier delivery.
FAU - Berger, Melvin
AU  - Berger M
AD  - Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA. 
      melvin.berger@uhhospitals.org
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Immunol Allergy Clin North Am
JT  - Immunology and allergy clinics of North America
JID - 8805635
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Animals
MH  - Clinical Protocols
MH  - Clinical Trials as Topic
MH  - Drug Administration Routes
MH  - Drug Approval
MH  - Drug Costs
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage/adverse 
      effects/economics/pharmacokinetics
MH  - Immunologic Deficiency Syndromes/physiopathology/psychology/*therapy
MH  - Injections, Subcutaneous
MH  - Pregnancy
MH  - Pregnancy Complications/immunology/therapy
MH  - Quality of Life
MH  - Treatment Outcome
RF  - 58
EDAT- 2008/10/23 09:00
MHDA- 2009/02/07 09:00
CRDT- 2008/10/23 09:00
PHST- 2008/10/23 09:00 [pubmed]
PHST- 2009/02/07 09:00 [medline]
PHST- 2008/10/23 09:00 [entrez]
AID - S0889-8561(08)00077-5 [pii]
AID - 10.1016/j.iac.2008.07.002 [doi]
PST - ppublish
SO  - Immunol Allergy Clin North Am. 2008 Nov;28(4):779-802, viii. doi: 
      10.1016/j.iac.2008.07.002.